Hims & Hers Health (NYSE:HIMS) Price Target Increased to $25.00 by Analysts at Bank of America

Hims & Hers Health (NYSE:HIMS) had its price objective upped by Bank of America from $23.00 to $25.00 in a research note released on Monday, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages have also commented on HIMS. Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. TD Cowen increased their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Piper Sandler restated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Finally, Jefferies Financial Group boosted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.21.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $21.52 on Monday. The firm’s 50 day moving average price is $17.36 and its 200-day moving average price is $17.76. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $25.74. The stock has a market cap of $4.62 billion, a P/E ratio of 269.03 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the firm posted ($0.03) EPS. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. As a group, equities analysts expect that Hims & Hers Health will post 0.22 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares in the company, valued at $362,342.55. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 841,076 shares of company stock worth $14,759,219 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Large investors have recently modified their holdings of the company. Lake Street Advisors Group LLC raised its position in Hims & Hers Health by 42.2% during the 3rd quarter. Lake Street Advisors Group LLC now owns 67,366 shares of the company’s stock valued at $1,241,000 after purchasing an additional 20,000 shares in the last quarter. Dakota Wealth Management purchased a new position in shares of Hims & Hers Health during the third quarter valued at $245,000. International Assets Investment Management LLC bought a new stake in shares of Hims & Hers Health in the third quarter valued at about $6,790,000. Lake Street Private Wealth LLC lifted its stake in Hims & Hers Health by 80.3% in the third quarter. Lake Street Private Wealth LLC now owns 103,447 shares of the company’s stock worth $1,905,000 after acquiring an additional 46,076 shares during the period. Finally, Venture Visionary Partners LLC bought a new position in Hims & Hers Health during the 3rd quarter worth about $238,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.